# TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

Source: https://onco.cc/trials/nct04969315/  
OnCo record `nct04969315` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TT-10 in renal cell carcinoma, prostate cancer, non-small-cell lung cancer and mesothelioma, run by Portage Biotech, now recruiting.

## Summary

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma is a phase 1/2 interventional study registered as NCT04969315 by Portage Biotech, with 35 participants planned, started 2023-06-23 and due to reach its primary completion in 2028-12-01. Interventions recorded: TT-10 and TT-4.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04969315
- Phase: 1/2
- Setting: A Phase 1/1b, Open-Label, First-in-Human Multicenter Study to Assess the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Pharmacodynamics of Oral TT-10 (an Adenosine 2A Receptor Antagonist), and TT-4 Diacid (an Adenosine 2B Receptor Antagonist), as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors
- Sponsor: Portage Biotech
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT04969315: https://clinicaltrials.gov/study/NCT04969315

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/nct04969315.json